| Theme | Digestive Diseases Related to Bacteria -- To Understand Etiology and Control of Clinicopathological Conditions | |
|---|---|---|
| Title | Evaluation of Helicobacter pylori Eradication Therapy and Clinical Benefits of Eradication | |
| Publish Date | 2007/08 | |
| Author | Masanori Ito | Department of Medicine and Molecular Science, Hiroshima University |
| Author | Masana Tatsugami | Department of Medicine and Molecular Science, Hiroshima University |
| Author | Yoshihiro Wada | Department of Medicine and Molecular Science, Hiroshima University |
| Author | Shinji Tanaka | Department of Endoscopy, Hiroshima University |
| Author | Masaharu Yoshihara | Health Service Center, Hiroshima University |
| Author | Kazuaki Chayama | Department of Medicine and Molecular Science, Hiroshima University |
| [ Summary ] | Helicobacter pylori (H. pylori) induces chronic gastritis and contributes to the occurrence of peptic ulcers as well as the gastric carcinogenesis. After eradication therapy, the recurrence of peptic ulcers decreases dramatically. Clinically, the urea breath test or the H. pylori stool antigen test (HpSA) test are beneficial to evaluate the outcome of eradication therapy. Histological gastritis, including inflammatory cell infiltration, atrophy and intestinal metaplasia, is improved through eradication therapy. However, it is still unclear whether eradication therapy can reduce the occurrence of gastric cancer. Even in cases with successful eradication therapy, intensive follow up should be carried out on these patients for gastric cancer screening. | |